Itamar Medical Ltd. (TASE:ITMR) is presenting at the American Heart Association convention in Orlando four studies which it claims demonstrate that the company's non-invasive Endo-PAT device can identify heart disease.
One study was the Farmington Heart Study, a multi-patient study conducted over several years, which is considered the premier cardiology study. The study examined links between warning signals from the Endo-PAT device and several risk factors associated with heart disease. The Farmington Heart Study is considered the foundation for establishing cardiology diagnostic and treatment protocols. Itamar Medical wants to integrate these protocols with the Endo-PAT.
The company also presented studies conducted at Harvard University and the Mayo Clinic, which achieved similar results.
The Endo-PAT is attached to the patient's finger and examines blood flow to it by measuring the expansion and contraction of the blood vessels. Itamar Medical believes that this signal provides evidence of the extent of damage to the endothelial (the inner surface of blood vessels), which is one of the basic aspects of heart disease. The Endo-PAT is cheap and easy to use.
Itamar Medical president CEO Israel Schreiber says that the company also has studies indicating that endothelial damage can be found in children, especially those living under stresss.
Published by Globes [online], Israel business news - www.globes-online.com - on November 6, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007